Co-expression of RON and MET is a Prognostic Indicator for Patients with Transitional-cell Carcinoma of the Bladder

Overview

Journal Br J Cancer

Specialty Oncology

Date 2005 May 5

PMID 15870710

Citations 50

Authors

H-L Cheng

H-S Liu

Y-J Lin

H H-W Chen

P-Y Hsu

T-Y Chang

C-L Ho

T-S Tzai

N-H Chow

Affiliations

Soon will be listed here.

Abstract

Recepteur d'Origine Nantais (RON) is a distinct receptor tyrosine kinase in the c-met proto-oncogene family. We examined the mutational and expression patterns of RON in eight human uroepithelial cell lines. Biological effects of RON overexpression on cancer cells were investigated in vitro, and the prognostic significance of RON and/or c-met protein (MET) expression was analysed in a bladder cancer cohort (n=183). There was no evidence of mutation in the kinase domain of RON. Overexpression of RON using an inducible Tet-off system induced increased cell proliferation, motility, and antiapoptosis. Immunohistochemical analysis showed that RON was overexpressed in 60 cases (32.8%) of primary tumours, with 14 (23.3%) showing a high level of expression. Recepteur d'Origine Nantais expression was positively associated with histological grading, larger size, nonpapillary contour, and tumour stage (all P<0.01). In addition, MET was overexpressed in 82 cases (44.8%). Co-expressed RON and MET was significantly associated with decreased overall survival (P=0.005) or metastasis-free survival (P=0.01) in 35 cases (19.1%). Recepteur d'Origine Nantais-associated signalling may play an important role in the progression of human bladder cancer. Evaluation of RON and MET expression status may identify a subset of bladder-cancer patients who require more intensive treatment.

Citing Articles

RON receptor tyrosine kinase as a critical determinant in promoting tumorigenic behaviors of bladder cancer cells through regulating MMP12 and HIF-2α pathways.

Wang K, Ye S, Jia X, Wang K, Meng X, Fei X Cell Death Dis. 2024; 15(11):844.

PMID: 39557851 PMC: 11574271. DOI: 10.1038/s41419-024-07245-w.

Ameliorative effect of Melatonin on 5-Fluorouracil-induced reproductive toxicity in male rats.

Almasi D, Kazemi S, Asghari M, Hosseini S, Moghadamnia A Daru. 2024; 32(2):675-687.

PMID: 39312086 PMC: 11554997. DOI: 10.1007/s40199-024-00537-8.

Therapeutic advances of targeting receptor tyrosine kinases in cancer.

Tomuleasa C, Tigu A, Munteanu R, Moldovan C, Kegyes D, Onaciu A Signal Transduct Target Ther. 2024; 9(1):201.

PMID: 39138146 PMC: 11323831. DOI: 10.1038/s41392-024-01899-w.

Tyrosine kinase receptor RON activates MAPK/RSK/CREB signal pathway to enhance CXCR4 expression and promote cell migration and invasion in bladder cancer.

Chen J, Wang K, Ye S, Meng X, Jia X, Huang Y Aging (Albany NY). 2022; 14(17):7093-7108.

PMID: 36103228 PMC: 9512502. DOI: 10.18632/aging.204279.

c-Met: A Promising Therapeutic Target in Bladder Cancer.

Feng Y, Yang Z, Xu X Cancer Manag Res. 2022; 14:2379-2388.

PMID: 35967753 PMC: 9374328. DOI: 10.2147/CMAR.S369175.

References

Zhou Y, He C, Chen Y, Wang D, Wang M . Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential. Oncogene. 2003; 22(2):186-97. DOI: 10.1038/sj.onc.1206075. View

Chen Y, Zhou Y, Fisher J, Wang M . Targeted expression of the receptor tyrosine kinase RON in distal lung epithelial cells results in multiple tumor formation: oncogenic potential of RON in vivo. Oncogene. 2002; 21(41):6382-6. DOI: 10.1038/sj.onc.1205783. View

Maggiora P, Lorenzato A, Fracchioli S, Costa B, Castagnaro M, Arisio R . The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp Cell Res. 2003; 288(2):382-9. DOI: 10.1016/s0014-4827(03)00250-7. View

Wada T, Qian X, Greene M . Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell. 1990; 61(7):1339-47. DOI: 10.1016/0092-8674(90)90697-d. View

Sidransky D, Frost P, von Eschenbach A, Oyasu R, Preisinger A, Vogelstein B . Clonal origin of bladder cancer. N Engl J Med. 1992; 326(11):737-40. DOI: 10.1056/NEJM199203123261104. View

Ronsin C, Muscatelli F, Mattei M, Breathnach R . A novel putative receptor protein tyrosine kinase of the met family. Oncogene. 1993; 8(5):1195-202. View

Sliwkowski M, Schaefer G, Akita R, Lofgren J, FITZPATRICK V, Nuijens A . Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem. 1994; 269(20):14661-5. View

Wang M, Ronsin C, Gesnel M, Coupey L, Skeel A, Leonard E . Identification of the ron gene product as the receptor for the human macrophage stimulating protein. Science. 1994; 266(5182):117-9. DOI: 10.1126/science.7939629. View

Heldin C . Dimerization of cell surface receptors in signal transduction. Cell. 1995; 80(2):213-23. DOI: 10.1016/0092-8674(95)90404-2. View

10.

Holmang S, Hedelin H, Anderstrom C, Johansson S . The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol. 1995; 153(6):1823-6; discussion 1826-7. View

11.

Pinkas-Kramarski R, Shelly M, Glathe S, Ratzkin B, Yarden Y . Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations. J Biol Chem. 1996; 271(32):19029-32. DOI: 10.1074/jbc.271.32.19029. View

12.

Collesi C, Santoro M, Gaudino G, Comoglio P . A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype. Mol Cell Biol. 1996; 16(10):5518-26. PMC: 231551. DOI: 10.1128/MCB.16.10.5518. View

13.

Santoro M, Collesi C, Grisendi S, Gaudino G, Comoglio P . Constitutive activation of the RON gene promotes invasive growth but not transformation. Mol Cell Biol. 1996; 16(12):7072-83. PMC: 231710. DOI: 10.1128/MCB.16.12.7072. View

14.

Chen Q, Seol D, Carr B, Zarnegar R . Co-expression and regulation of Met and Ron proto-oncogenes in human hepatocellular carcinoma tissues and cell lines. Hepatology. 1997; 26(1):59-66. DOI: 10.1002/hep.510260108. View

15.

Crew J, OBrien T, Bradburn M, Fuggle S, Bicknell R, Cranston D . Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res. 1997; 57(23):5281-5. View

16.

Maggiora P, Marchio S, Stella M, Giai M, Belfiore A, De Bortoli M . Overexpression of the RON gene in human breast carcinoma. Oncogene. 1998; 16(22):2927-33. DOI: 10.1038/sj.onc.1201812. View

17.

Ho C, Mou T, Chiang P, Weng C, Chow N . Mini chamber system for long-term maintenance and observation of cultured cells. Biotechniques. 2005; 38(2):267-73. DOI: 10.2144/05382RR03. View

18.

Koo S, Kwon K, Ihm C, Jeon Y, Park J, Sul C . Detection of genetic alterations in bladder tumors by comparative genomic hybridization and cytogenetic analysis. Cancer Genet Cytogenet. 1999; 110(2):87-93. DOI: 10.1016/s0165-4608(98)00193-9. View

19.

Danilkovitch A, Donley S, Skeel A, Leonard E . Two independent signaling pathways mediate the antiapoptotic action of macrophage-stimulating protein on epithelial cells. Mol Cell Biol. 2000; 20(6):2218-27. PMC: 110838. DOI: 10.1128/MCB.20.6.2218-2227.2000. View

20.

Follenzi A, Bakovic S, Gual P, Stella M, Longati P, Comoglio P . Cross-talk between the proto-oncogenes Met and Ron. Oncogene. 2000; 19(27):3041-9. DOI: 10.1038/sj.onc.1203620. View